JPRN-jRCT2080223628已完成3 期
An Intra-Subject Dose-Adjustment Study of KHK7580 for the Treatment of Hypercalcemia in Patients with Parathyroid Carcinoma or Primary Hyperparathyroidism who are Unable to Undergo Parathyroidectomy or Relapse after Parathyroidectomy
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 18
研究概览
简要总结
Evocalcet demonstrated long-term effectiveness in reducing serum cCa concentrations and safety without any unexpected drug related TEAEs in PHPT patients.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Personally submitted written voluntary informed consent to participate in the study
- •- Patients with a diagnosis of parathyroid carcinoma or primary hyperparathyroidism who are unable to undergo parathyroidectomy or relapse after parathyroidectomy.
- •- Corrected serum calcium level is > 11.3 mg/dL at screening.
排除标准
- •- Patients receiving cinacalcet hydrochloride within 2 weeks before screening
- •- Patients diagnosed with hypercalcemia associated with malignant tumors other than parathyroid carcinoma.
研究者
相似试验
已完成
3 期
Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary HyperparathyroidismPrimary HyperparathyroidismParathyroid CarcinomaNCT03280264Kyowa Kirin Co., Ltd.18
已完成
不适用
Vitamin K2 for Reduction the Calcium at Carotid Bifurcation in Patients With Subcritical LesionsCarotid PlaquesNCT02970084Scientific Institute San Raffaele60
已完成
不适用
Clinical efficacy of intravenous calcium-sensing receptor agonist (etelcalcetide hydrochloride) for secondary hyperparathyroidismEnd-stage renal diseaseJPRN-UMIN000027408Saitama Tsukinomori Clinic32
已完成
4 期
Relypsa For ED Acute Hyperkalemia Control and Reduction (REDUCE)Kidney Failure, ChronicNCT02933450Baylor College of Medicine43
终止
3 期
A Study to Determine Effective Prophylaxis and Treatment of Nelfinavir-Associated DiarrheaDiarrheaNCT00650637Pfizer17